International veterinary epilepsy task force consensus proposal: outcome of therapeutic interventions in canine and feline epilepsy
Heidrun Potschka, Andrea Fischer, Wolfgang Loescher, Ned Patterson, Sofie Bhatti, Mette Berendt, Luisa De Risio, Robyn Farquhar, Sam Long, Paul Mandigers, Kaspar Matiasek, Karen Munana, Akos Pakozdy, Jacques Penderis, Simon Platt, Michael Podell, Clare Rusbridge, Veronika Stein, Andrea Tipold, Holger A Volk
BMC Veterinary Research | BIOMED CENTRAL LTD | Published : 2015
Following reimbursements, fees and funding have been received by the authors in the last three years and have been declared in the competing interest section. WL, CR, RGF, HAV, KM, MP and JP have received fees for acting as a consultant for Boehringer Ingelheim (WL, KM, MP: consultancy during development and approval of imepitoin; CR: pain consultancy; RGF, JP, HAV: consultancy pre and post launch of imepitoin). AT has been an advisor for Boehringer Ingelheim. SFMB, HAV and AT have been responsible principal investigator of several research studies concerning imepitoin financed by Boehringer Ingelheim. SFMB, HAV, JP, HP, MB, CR and AF received speaking fees from Boehringer Ingelheim. HP received consulting and speaking fees and funding for a collaborative project from Eisai Co. LTD. HAV received funding for a collaborative project from Desitin and Nestle Purina Research. AF and LDR received reimbursements from Boehringer Ingelheim. LDR has received consulting and speaking fees from Vetoquinol. MP has received consultant fees for Aratana. The other authors declared that they have no competing interests.